# Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension

> **NCT03267329** · PHASE4 · COMPLETED · sponsor: **Yuhan Corporation** · enrollment: 80 (actual)

## Conditions studied

- Hypertension
- Dyslipidemia

## Interventions

- **DRUG:** Duowell®
- **DRUG:** Telmisartan

## Key facts

- **NCT ID:** NCT03267329
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-11
- **Primary completion:** 2020-09-02
- **Final completion:** 2020-09-02
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2021-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03267329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03267329, "Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03267329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*